STERIS Corporation, a wholly owned operating subsidiary of STERIS plc, agreed to buy Xodus Medical, Inc. for $2.1 billion in cash on October 12, 2026, according to a corporate press release published on the same day. The buyer plans to extract approximately $300 million in tax benefits from the transaction structure, bringing the net effective purchase price down to $1.8 billion, a figure confirmed by Reuters on October 12, 2026. The acquisition brings Xodus Medical and its affiliated entities into the STERIS portfolio of medical equipment and sterilization services, closing a substantial gap in the buyer’s surgical product offerings.
Medical device manufacturers continue to consolidate their supply chains and operating room product lines as hospital systems demand bundled purchasing agreements and single-vendor procurement strategies. STERIS operates an aggressive acquisition strategy in the surgical space, buying specialized manufacturers rather than developing competing products internally. Xodus Medical manufactures operating room essentials, and this purchase gives STERIS immediate control over a profitable catalog of surgical safety products without the friction of building market share from a zero base. The transaction relies entirely on debt financing in a high-interest environment, a decision that indicates the buyer’s confidence in the target’s cash flow generation capabilities and operating margins.
Xodus Medical expects to generate $135 million in adjusted earnings before interest and taxes during calendar year 2026, according to the October 12 STERIS press release. This adjusted figure accounts for $14 million in charges tied to a recently terminated royalty arrangement, meaning the target’s unadjusted operating income sits at $121 million. A contingent consideration structure allows the sellers to earn up to an additional $150 million if the business hits specific performance targets by the end of calendar year 2028. The inclusion of this earnout mechanism bridges valuation expectations between the buyer and sellers while protecting STERIS from potential revenue shortfalls in the immediate post-merger integration period.
Deal terms at a glance
| Acquirer | STERIS Corporation, a subsidiary of STERIS plc |
| Target | Xodus Medical, Inc. and certain related affiliates |
| Headline price | $2.1 billion |
| Effective net price | $1.8 billion (adjusted for $300 million in expected tax benefits) |
| Consideration | Cash at closing |
| Contingent consideration | Up to $150 million based on 2028 performance targets |
| Financing | Primarily debt funded |
| Conditions | Customary closing conditions and regulatory approvals |
| Expected timetable | Closing by December 31, 2026 |
Advisers
Goldman Sachs & Co. LLC acted as the exclusive financial adviser to STERIS, according to the October 12 press release issued by STERIS. The investment bank provided valuation models, structured the debt financing parameters, and evaluated the tax benefit framework that reduced the net effective purchase price. Jones Day acted as legal counsel for the buyer, managing the definitive agreement drafting, regulatory compliance reviews, and antitrust filing preparations required for closing.
J.P. Morgan acted as the exclusive financial adviser to Xodus Medical, as stated in the same STERIS press release. The bank negotiated the $2.1 billion headline valuation and structured the contingent earnout mechanism that could deliver an additional $150 million to the target’s ownership group by 2028. Morgan, Lewis & Bockius LLP acted as legal counsel for Xodus Medical, reviewing the transaction documents and representing the sellers in discussions regarding post-closing performance targets and royalty termination charges.
How the deal came about
STERIS and Xodus Medical did not disclose the precise timeline of their private negotiations or the initial outreach dates in the October 12 press release. Neither company published a background of the merger document, and no regulatory proxy filing detailing the bidding process was available on the Securities and Exchange Commission database on October 12, 2026. The transaction surfaced publicly when STERIS issued its definitive agreement announcement before the market opened.
According to a Reuters report published on October 12, 2026, Xodus Medical did not disclose any rival bids. Fitch Ratings published a credit commentary on October 12, 2026, which similarly contained no mention of competing offers or auction processes. The negotiations resulted in a definitive agreement that STERIS and Xodus Medical executives signed in early October before releasing the news to the financial markets.
The structure of the agreement indicates complex negotiations regarding the target’s valuation and tax liabilities. The parties agreed to a structure that generates $300 million in cash tax benefits for STERIS, lowering the actual cash impact on the buyer’s balance sheet, according to the STERIS press release. The inclusion of an earnout tied to calendar year 2028 performance shows that the buyer and sellers negotiated to bridge differing views on the target’s future growth trajectory.
Valuation and comparables
STERIS agreed to pay a gross headline value of $2.1 billion, which yields an enterprise value to revenue multiple of 8.57x based on the target’s projected calendar year 2026 revenue of $245 million. This calculation uses figures provided directly in the October 12 STERIS press release. When applied to the target’s projected 2026 adjusted EBIT of $135 million, the headline price implies a multiple of 15.56x.
The valuation multiples drop when accounting for the transaction’s tax structure. Using the net effective purchase price of $1.8 billion, the enterprise value to revenue multiple falls to 7.35x. The net price to adjusted EBIT multiple calculates to 13.33x. The STERIS press release did not disclose the target’s standalone earnings before interest, taxes, depreciation, and amortization.
Historical comparable transactions in the medical device and surgical equipment sectors were not cited by the buyer in its press release. The October 12 Reuters report did not list comparable deals or benchmark multiples for recent acquisitions in the surgical suite manufacturing space. The calculation inputs for Xodus Medical rely exclusively on the forward-looking projections published by STERIS.
The $135 million adjusted EBIT projection builds upon a base GAAP operating income estimate of $121 million, according to the October 12 STERIS press release. The buyer adjusted this figure by adding back $14 million in charges related to a recently terminated royalty arrangement. This adjustment improves the target’s implied profitability metrics and lowers the transaction multiples calculated by financial analysts reviewing the deal.
The maximum transaction value reaches $2.25 billion if Xodus Medical achieves all performance targets required to unlock the $150 million earnout in 2028. Based on the $245 million revenue projection for 2026, the maximum payout yields a gross multiple of 9.18x revenue. Neither company disclosed the specific financial thresholds required to trigger the earnout payments.
Financing and structure
STERIS intends to fund the acquisition primarily through debt, according to the October 12 press release and a matching report from Reuters. The buyer did not specify the exact debt instruments it plans to use, and the press release did not name specific credit facilities, term loans, or bridge arrangements secured for the transaction.
Fitch Ratings affirmed STERIS plc’s Long-Term Issuer Default Rating at ‘BBB’ with a Stable outlook on October 12, 2026. The credit rating agency reviewed the transaction parameters and concluded that the buyer possesses sufficient headroom within its existing credit profile to absorb the debt required to fund the $2.1 billion cash purchase.
The acquisition increases the buyer’s leverage ratios in the near term. Fitch Ratings projects that the pro forma EBITDA leverage for STERIS will measure approximately 2.1x by the end of fiscal year 2027. The agency based this projection on the combined cash flows of the existing STERIS business and the newly acquired Xodus Medical operations.
STERIS plans to provide the financial markets with an updated fiscal 2027 financial outlook after the transaction closes, according to its October 12 press release. This upcoming guidance will incorporate the debt servicing costs and the exact capital structure implemented to fund the cash consideration. Until that publication, the specific interest rates and maturity dates of the acquisition debt remain undisclosed.
Risks, conditions and key dates
The acquisition process requires several steps before the companies can integrate their operations. The definitive agreement contains standard clauses and requirements that the parties must satisfy over the coming months.
- October 12, 2026: STERIS and Xodus Medical announce the definitive agreement for the $2.1 billion cash transaction.
- Pending: The parties must submit filings to regulatory bodies to satisfy antitrust review requirements. The STERIS press release did not disclose the specific jurisdictions requiring approval.
- Pending: The companies must clear customary closing conditions as defined in the merger agreement. Neither company disclosed the existence of any material adverse change clauses or specific termination fees.
- December 31, 2026: The transaction is expected to close by this date, according to the October 12 statements from STERIS and Reuters.
- Post-Closing: STERIS will publish updated fiscal 2027 financial guidance incorporating the Xodus Medical business.
- Calendar Year 2028: The performance period for the $150 million contingent earnout concludes.
Where reports disagree
The primary sources and financial news outlets report identical facts regarding the transaction parameters. There are no disagreements between the figures published by the buyer and those reported by external media.
STERIS stated the headline purchase price is $2.1 billion in its October 12 press release. Reuters reported the same $2.1 billion figure on October 12.
STERIS stated the effective net purchase price is $1.8 billion after accounting for tax benefits in its October 12 press release. Reuters reported the same $1.8 billion net figure on October 12.
STERIS projected the target’s calendar 2026 revenue at $245 million in its October 12 press release. Reuters reported the same $245 million revenue expectation on October 12.
STERIS announced an expected closing date by December 31, 2026, in its October 12 press release. Reuters reported the identical target closing timeline on October 12.
Sources
Press and analysis
- Fidelity, Mergers and Acquisitions
- KSL, Steris Buys Surgical Products Maker Xodus Medical for 21 Billion
- Investing.com, Steris to Acquire Xodus Medical for 21 Billion
- Fitch Ratings, Fitch Affirms Steris Ratings Following Xodus Acquisition Announcement
Facts as of 12 October 2026.
